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Diabetes mellitus is a metabolic disease that is defined by relative or absolute deficiency of 
insulin secretion. Diabetic kidney disease seems to be one of the most frequent complications 
of diabetes mellitus. Based on evidence, increased free-radical formation and/or diminished 
antioxidant defenses induce oxidative stress that is implicated in the pathogenesis of diabetic 
kidney disease. It is evident that diabetic state induces oxidative stress through different 
signaling pathways as well as reactive oxygen species (ROS) formation that attributes to the 
activation of various downstream signaling cascade leading to structural the way to structural 
and functional changes in kidney.
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Implication for health policy/practice/research/medical education:
It is evident that diabetic state induces oxidative stress through different signaling pathways as well as reactive oxygen species 
(ROS) formation that attributes to the activation of various downstream signaling cascade leading to the way to structural and 
functional changes in kidney.
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Introduction
Diabetes mellitus is a metabolic disease that is defined by 
relative or absolute deficiency of insulin secretion. Today, 
diabetes is known to be one of the primary causes of 
mortality and morbidity in the world (1-3). Complications 
of disease progression include retinopathy, nephropathy, 
cardiomyopathy, hepatopathy, and neuropathy. Diabetes is 
generally comprised of several subcategories such as type 1 
diabetes mellitus which demonstrated by absolute insulin 
deficiency caused by cell-specific autoimmune destruction 
of the insulin producing beta cells in the pancreas. Type 2 
diabetes which is occurred as a result of the weakness of 
beta cells to compensate for insulin secretion or selective 
loss of pancreatic beta cells due to viral infections or toxic 
injury leading to insulin insufficiency (4). Diabetic kidney 
disease is one of the critical problems of diabetes mellitus 
which its prevalence has been increasing in worldwide 
(5). Generally, chronic hyperglycemia increases oxidative 
stress factors followed by modifying the structure and 
function of proteins and lipids significantly. It also induces 
glycoxidation and peroxidation. Thus, hyperglycemia 
results to auto-oxidation of glucose, glycation of proteins 
and activation of polyol mechanism. Hyperglycemia-
induced oxidative stress has been singled out as one of the 
main links between diabetes and diabetic complications. 
Therefore; hyperglycemia induces autoxidation of 
glucose and glycosylation of proteins by generation of 
free radicals thus, increases the reactive oxygen species 
(ROS) accompanied by a reduction in antioxidant activity 
which leads to the occurrence of oxidative stress. These 
can cause endothelial dysfunction, insulin resistance, and 
alterations in the proportion and functions of pancreatic 
𝛽 cells and ultimately leads to diabetic microvascular and 
macrovascular complications (6,7). Based on evidence, 
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ROS induces several cellular signaling cascades which 
in turn promote transcription of stress-related genes and 
development of diabetic complications including nuclear 
factor kappa-light-chain-enhancer of activated B cells 
(NF-𝜅B), an activated nuclear transcription factor by an 
elevation in ROS. This phenomenon ultimately results 
in transcription of pro-inflammatory proteins. Increase 
in ROS can activate pro-inflammatory chemokines, 
tumor necrosis factor (TNF-𝛼), macrophage chemotactic 
proteins (MCP-1), and interleukins (IL-1β and 6) that have 
been implicated in the progression of diabetes to diabetic 
complications (8). Likewise, hyperglycemia can induce 
ROS elevation and can lead to activation of apoptosis 
signaling pathways in tissues by Bax-caspase pathway. This 
in turn can lead to reduction of electrochemical gradient 
through the mitochondrial membrane causing a leakage of 
mitochondrial cytochrome C into cytoplasm. This process 
also may activate apoptosis (9). This review article aimed 
to discuss the pathophysiological mechanisms of renin-
angiotensin system (RAS) inhibition by herbal plants 
and update the diabetic nephropathy, oxidative stress and 
antioxidant agents. 
Materials and Methods
For this review, we used a variety of sources by searching 
through Web of Science, PubMed, EMBASE, Scopus and 
directory of open access journals (DOAJ). The search was 
performed using combinations of the following key words 
and or their equivalents; diabetic nephropathy, reactive 
oxygen species, diabetic kidney disease, chronic kidney 
disease, microalbuminuria and advanced glycation end 
products.
Diabetic kidney disease
Diabetic kidney disease seems to be one of the most 
frequent complications of diabetes mellitus. Based 
on evidence, increased free-radical formation and/
or diminished antioxidant defenses induce oxidative 
stress that is implicated in the pathogenesis of diabetic 
kidney disease (10-12). Antioxidants include enzymatic 
antioxidants such as superoxide dismutase (SOD), catalase 
(CAT), glutathione S-transferase (GST), glutathione 
peroxidase (GPx), and non-enzymatic antioxidants such 
as reduced glutathione (GSH), uric acid, carotenoids, 
flavonoids, lipoic acid, and vitamins A, C, and E. 
Superoxide anion (∙O2−) dismutates are manufactured to 
produce water by CAT and GPx. Enzymatic antioxidant of 
GST converts reactive electrophilic species to hydrophilic 
forms then are conjugated by GSH and easily excreted. 
Non-enzymatic antioxidants like vitamins C and E and 
lipoic acid are involved in the termination of the lipid 
peroxidation process (13,14). 
Oxidative stress and diabetes
Generally, oxidative stress happens when the proportion 
of production of ROS into the cell exceeds their normal 
rates, which leading to cellular and tissue damage (15). 
Therefore, imbalance of oxidants/antioxidant ratio 
causes an alteration in the normal redox signaling of the 
cell that induces impairment in several pathways of the 
cell’s metabolism. ROS, free radicals or non-free radical 
compounds, can be either useful or harmful to the cells. 
Free radicals of ROS include superoxide (∙O2−), hydroxyl 
(∙HO), peroxyl (∙RO2−), hydroperoxyl (∙HRO2−), and 
non-radical of ROS include hydrogen peroxide (H2O2) 
and hydrochlorous acid (HOCl). Hyperglycemia-
induced oxidative stress can inhibit the secretion of 
insulin in pancreatic beta cell through the activation of 
an uncoupling protein-2 (UCP-2) which lowers the ATP/
ADP ratio by leaking protons in the β cell. Also, ROS can 
leak into cell membranes and damage pancreatic β cells. 
Some researchers showed overproduction of free radicals 
such as superoxide anion in β cells leading to activation 
of stress-signaling processes which are able to induce 
downstream effectors such as NF-𝜅B which may lead 
to β cell apoptosis and dysfunction in the end reducing 
insulin secretion. Also, high concentrations of hydrogen 
peroxide directly with the phosphatidylinositol-3-kinase 
dependent pathway induce insulin signaling leading to 
insulin resistance prior to the onset of diabetes. Some 
reports have detected that in presence of hyperglycemia, 
hyperlipidemia can generate more ROS imposing β cell 
dysfunction. Likewise, high free fatty acids affect ROS 
overproduction leading to mitochondrial DNA damage 
and pancreatic β cell dysfunction (16).
Oxidative stress and diabetic nephropathy 
Diabetic kidney disease is considered as one of the major 
micro-vascular problems of diabetes mellitus and has 
become the most general single cause of end-stage kidney 
disease. It is defined traditionally by kidney morphological 
and functional modifications like; glomerular 
hyperfiltration, glomerular and kidney hypertrophy, 
increased urinary albumin excretion, increased glomerular 
basement membrane (GBM) thickness, and mesangial 
expansion and also accumulation of extracellular proteins 
comprising laminin, collagens and fibronectin (17,18). It 
is now clear that multiple pathways are involved in the 
pathogenesis of diabetic kidney disease like; hexosamine 
pathway, protein kinase C (PKC) pathway, formation of 
advanced glycation end products (AGEs), polyol pathway, 
growth factors, cytokines and free radicals. It should 
be noted that all these paths are induced by imbalance 
between oxidative stress and antioxidant elements (19).
Oxidative stress is a poisonous phenomenon within the 
body that principally is illustrated by disparity of cellular 
oxidation/reduction levels. On the other hand, it occurs 
when reduction of the normal antioxidant defense 
system of the human body such as CAT, GPx, SOD and 
glutathione reductase (GR) is counteracted. High glucose 
level, either due to resistance of cells to insulin or lack of 
insulin synthesis, plays an important role in production of 
ROS through the activation of various cellular responses 
thereby leading to deleterious effects like diabetic kidney 
disease. There are several factors which are involved in 
generation of oxidative stress during diabetes such as 
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peroxyl, hydroxyl, superoxide and many other reactive 
compounds hydrogen peroxide (H2O2), nitric oxide (NO), 
nitrous oxide (HNO2), hydrochlorous acid (HOCl) and 
nitrogen dioxide (NO2). Also, the evidence show that 
oxidative stress during diabetic kidney disease eventually 
results to the knocking down of normal kidney homeostasis 
and its proper functioning. It is well established that 
augmented ROS construction in kidneys of both type 1 
and type 2 DM can be affected individuals through both 
enzymatic and non-enzymatic pathways (18). 
On the evidence, high glucose acts by the activation 
of PKC in diabetic glomeruli via de novo synthesis of 
diacylglycerol (DAG). Then, PKC creates ROS which 
finally cause activation of PKC thus causing enhancement 
of mesangial expansion, GBM thickening and dysfunction 
of endothelial cells running to diabetic kidney disease. 
Furthermore, high glucose levels induce isoforms of 
nicotinamide adenine dinucleotide phosphate oxidases 
(NOXs), especially NOX-4 which results to endothelial 
dysfunction, inflammation and consequently apoptosis. 
Also, the others pathways of glucose auto-oxidation 
such as increased formation of AGEs, polyol pathway 
flux and glycation of proteins are involved in causing 
direct and indirect kidney injury by producing extensive 
proportion of ROS. Accordingly, diabetic kidney 
disease is also associated with an intensification in RAS 
activity, as well as aldosterone production which play an 
important and direct role in the creation and activation 
of ROS resulting to kidney injury. On the other hand, 
high glucose level leads to the induction of transforming 
growth factor-(TGF-β) presentation in the glomerular and 
tubulointerstitial compartments that enhances the level of 
TGF-β leading to kidney enlargement, glomerulosclerosis 
and tubulointerstitial fibrosis in diabetic kidney disease 
(18-20). Under oxidative stress situation, vascular 
endothelial growth factor (VEGF), a protein secreted by 
the podocytes and the mesangial renal cells that plays a 
role in the extension of diabetic kidney disease. In fact, 
VEGF is increased by the activity of hypoxia-inducible 
factor (HIF-1α) and augmented level of angiotensin II. 
Some literatures reported that VEGF may interfere with 
the pathway of phosphoinositide 3-kinase/protein kinase 
B (PI3K/PKB) and presentation of endothelial nitric 
oxide synthase (eNOS). Therefore; VEGF indirectly 
stimulates the level of intracellular ROS by provocation 
the generation of peroxynitrite (ONOO−). Consequently, 
ROS production by various pathways results to the 
activation of downstream molecules like NF-κB, TGF-β 
and p38 mitogen activated protein kinases (p38 MAPK), 
pathway ultimately results to nephropathic condition by 
activating an array of diverging signaling cascades (20).
Antioxidant strategies in diabetic nephropathy
Antioxidant compounds are important for two main 
reasons. First, they can reduce the harmful effects of free 
radicals not only by preventing their formation but also 
by scavenging and inactivating free radicals or improving 
natural defense systems by inducing the activities of 
antioxidant enzymes and regenerating other proteins 
involved in antioxidant pathways. There are several 
strategies employed in the use of different antioxidants 
to contrast diabetic nephropathy. The choice of strategy 
depends on the type, structure, and concentration of 
the antioxidants. In addition, the stage, severity and 
prevalence of the disease are very important (21,22).
Vitamin E and diabetic nephropathy
Vitamin E, a lipid-soluble vitamin, includes the 
stereoisomers a-tocopherol, b-tocopherol, g-tocopherol, 
d–tocopherol and d–tocotrienol that tocopherol and 
tocotrienol stereoisomers and their metabolites appear 
to have potent biological properties. Generally, vitamin 
E detoxifies free radicals directly and also interacts with 
recycling processes to create reduced forms of A and C 
vitamins. Vitamin E also has a number of biological 
activities such as immune stimulatory and preventive 
activity of genetic changes by inhibition of DNA damage. 
Vitamin E primarily serves as a chain-breaking antioxidant 
to prevent lipid peroxidation. Some literatures have shown 
that tocopherol can modulate cell signaling pathways by 
inhibiting PKC. Tocopherols also have gene regulatory 
functions because they potentially serve as ligands for the 
transcription factor peroxisome proliferators-activated 
receptor-γ (PPAR-γ). The tocopherol concentrations of 
plasma are lower in diabetics compared to controls and 
appear to be even lower in diabetics with complications like 
microangiopathy than diabetics without complications 
(23).
Q10 and diabetic nephropathy
Coenzyme Q10 (COQ10), an endogenous lipid-soluble 
micronutrient, is found in most living cells in the body 
that is a key component in the electron transport chain 
of the mitochondria, serving in the process of adenosine 
triphosphate (ATP) synthesis. Also, CoQ10 is a powerful 
antioxidant that scavenges free radicals and provides 
protection to cells in oxidative stress condition. Based 
on evidence, individuals with diabetic kidney disease 
often have deficiency in CoQ10 plasma levels compared 
to normal healthy subjects. Because of its antioxidant 
property, it is accepted that CoQ10 deficiency may 
impair the body’s defensive mechanisms against oxidative 
stress induced by hyperglycemia (24). Therefore, it is 
recommended that CoQ10 plays an important role in the 
pathogenesis of type 2 diabetic mellitus. Also, it is suggested 
that CoQ10 deficiency is a precipitating factor for diabetic 
kidney disease (25). Researchers have explored the effects 
of CoQ10 on glycemic control among individuals with 
type 2 diabetic mellitus and they investigated that daily 
supplementation of CoQ10 (200 mg/d) for 12 weeks 
effectively decreased HbA1c levels among patients with 
uncomplicated type 2 diabetic mellitus and dyslipidemia. 
In addition, the researchers suggested that CoQ10 
provides protection to β cells through its antioxidant 
property, down-regulation of insulin receptors to improve 
insulin action and provides protection to the kidneys in 
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the event of diabetic nephropathy. It is clear that CoQ10 
is a scavenger of ROS and provides protection to cells, 
especially mitochondria from oxidative damage condition 
(26). 
Alpha-lipoic acid and diabetic nephropathy 
Alpha-lipoic acid (ALA), one of the most successful 
antioxidants in clinical trials, is the only antioxidant 
capable of dissolving in both water and fats. It can be 
biosynthesized in plants and animals then metabolized to 
dihydrolipoic acid (DHLA) upon uptake into cells. Based 
on evidence, ALA and DHLA are powerful free radical 
scavengers that are also involved in the regeneration of 
vitamins C and E and oxidized glutathione within the cells. 
Also, ALA is a cofactor for a number of mitochondrial 
enzymes that can decrease lipid peroxidation, reduce 
oxidative stress, and improve blood flow in kidney. Some 
studies have shown that ALA reduces oxidative stress by 
inhibiting hexosamine and AGEs pathways (27). 
Vitamin D and diabetic nephropathy
There is an inverse relationship between serum 
25-hydroxyvitamin D [25(OH) D3] levels or prevalence 
of diabetes mellitus and its complications. Also, 
some previous studies showed an improvement of 
diabetic kidney disease symptoms after vitamin D 
supplementation. It has been demonstrated that vitamin 
D might reverse the progression of diabetic kidney disease 
for instance improving glucose metabolism, minimizing 
RAS activation, and finally reducing fibrosis (28). A study 
showed that vitamin D receptor was highly expressed 
in the kidney. Hence the kidney could be considered a 
classic vitamin D target organ. Also, an inverse correlation 
was reported between the prevalence of albuminuria 
and serum 25(OH)D3 concentration. The mechanism 
for relationship between vitamin D and diabetic kidney 
disease remains unclear however various animal studies 
have shown that knockout of the vitamin D receptor in 
diabetic mice is accompanying by severe albuminuria 
and glomerulosclerosis. Therefore, vitamin D might slow 
down diabetic kidney disease progression by delaying 
destruction of b-islet cells, enhancing insulin secretion, 
and consequently assisting in glucose metabolism (29,30).
Flavonoids and diabetic nephropathy
Flavonoids, the largest and the most important group of 
polyphenolic compounds in plants, are found in fruits, 
vegetables, grains, bark, roots, stems, flowers, tea, and 
wine. Flavonoids are made up of several subclasses that 
can scavenge free radicals and chelate metals for example; 
pro-anthocyanidin and luteolin have been shown to 
possess antioxidant activities which protect against 
diabetic kidney disease (31). 
Conclusion
The advantage of knowledge of powerful antioxidants is 
finding the modalities for greater insight in the treatment 
of diabetic kidney disease. In this review, we focused 
on understanding of diabetes induced oxidative stress 
through different signaling pathways as well as ROS 
formation that attributes to the activation of various 
downstream signaling cascade leading the way to 
structural and functional changes in kidney. We discussed 
that the administration of the anti-oxidative agents was 
able to restore the antioxidant defense system thereby 
preventing ROS mediated injuries. 
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